Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.

Mayo Clinic researchers found that mutations in these genes could be found in nearly 6 percent of patients and argued for germline genetic testing for patients.

The researchers designed a transcriptome sequencing assay that identifies clinically relevant gene fusions in 541 genes.

Using whole-genome sequencing, the researchers uncovered pathogenic variants in cancer-predisposing genes in 15 percent of patients with multiple primary tumors.

With its purchase of decision support technology maker Interactive Biosoftware, Sophia looks to extend its AI platform deeper into NGS interpretation.

With sequence data for more than 118,000 tumors profiled at Foundation Medicine, investigators tracked PDL1 amplification prevalence and possible treatment implications.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.

In silico molecular biology tools, electronic lab notebooks, and systems for registration,
sample management, workflow management, and request management form the
foundation of informatics for biologics R&D.

When building out their informatics, most R&D organizations evaluate these solutions
independently, by checking off a list of required features. This is a good starting point, but
what are you missing by not evaluating the platform capabilities of these solutions?

The BD Rhapsody Single-Cell Analysis System empowers and streamlines single-cell research with a complete system of tools, including reagents and analysis software, that work together to meet neuroscience experimental needs. Neuroscientists’ ability to identify and characterize individual cells in the nervous system opens the door to finding pathogenic cells, regenerative cells, and pathways that drug manufacturers can exploit for the discovery of therapeutics for neurodegenerative disease.

Highly predictive patient-derived xenograft (PDX) models can predict clinical efficacy for oncology drug candidates better than traditional cell line-derived preclinical models. This white paper describes how PDX models can be used in Mouse Clinical Trials, upending the traditional paradigm in animal studies and providing a better perspective of patient-to-patient heterogeneity.